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Conclusions. Administration of combinated drugs increase daily diuresis, level of megnesium 
and level of urine pH which is going to alkalization of urine as a result of expulsion of 
desintegrated fragments was increasing, as well as reduced attacks of renal colic.  
Key words: urinary stone disease, treatment, combination drugs, urine pH  
 
79. TREATMENT OF KIDNEY CANCER  
Author: Sorina-Mihaela Rojnita  
Scientific adviser: Oprea Andrei, MD, PhD, Associate Professor, Department of Urology and 
Surgical Nephrology. Nicolae Testemitanu State University of Medicine and Pharmacy, 
Chisinau, Republic of Moldova 
 
Introduction. Renal cell carcinoma is the most common type of kidney cancer in adults. It 
accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from 
the kidney. In recent years, several approaches of active and passive immunotherapy have been 
studied extensively in clinical trials of patients with RCC. Recent advances in molecular 
biology have led to the development of novel agents for the treatment.  
Aim of the study. To describe the contemporary standard of treatment for kidney cancer, and 
their comparison with the classical methods of treatment, the current standard of care, the role 
of prognostic criteria, such as those from the International Metastatic Renal Cell Carcinoma 
Database Consortium (IMDC) criteria.   
Materials and methods.. The study presents the magazine of literature (Medline, Scopus, 
PubMed, School google, etc.)  
Results. Radical nephrectomy remains the mainstay of initial treatment for patients with renal 
tumours without evidence of metastatic disease. The goal of partial nephrectomy is the 
complete elimination of the primary tumor, while maintaining the highest possible amount of 
parenchymal renal health. Partial nephrectomy is indicated for the patient with T1 tumors 
(according to TNM staging for international cancer control) and a normal contralateral kidney.  
In patients with unresectable and/or metastatic cancers, tumor embolization, external-beam 
radiation therapy, and nephrectomy can aid in the palliation of symptoms caused by the primary 
tumor or related ectopic hormone or cytokine production.  The drugs used in chemotherapy are 
floxuridine, 5-fluorouracil and vinblastine. But unfortunately, these drugs are proven resistant 
to renal cell carcinoma.  In contrast with chemotherapy, targeted treatments attack specific 
molecules and cell mechanisms which are required for carcinogenesis and tumor growth. This 
specific targeting helps to spare healthy tissues and reduce side effects. Targeted cancer 
therapies may be more effective than current treatments and less injurious to normal cells. 
Research has revealed that addition of these targeted treatments to immunotherapy, or using 
them as a substitute of immunotherapy, nearly doubles the time duration so as to stop cancer 
growth.  Systemic therapy in metastatic renal cell carcinoma includes Sunitinib and pazopanib 
that are approved treatments in first-line therapy for patients with favorable- or intermediate-
risk clear cell RCC. Temsirolimus has proven benefit over interferon-alfa in patients with non-
clear cell RCC. Systemic therapy has demonstrated only limited effectiveness.  New agents 
including the small molecule targeted inhibitors like sorafenib, bevacizumab, axitinib and the 
monoclonal antibody bevacizumab have shown anti-tumour activity in randomised clinical 
trials and have become the standard of care for most patients.  
Conclusions.  For patients with surgically resectable RCC, the standard of care is surgical 
excision by either partial or radical nephrectomy with a curative intent. By contrast, those with 
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inoperable or metastatic RCC typically undergo systemic treatment with targeted agents and/or 
immune checkpoint inhibitors.  
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Introduction. A great number of bladder cancer cases are due to the carcinogenic substances 
that affect the bladder urothelium, which is eliminated with urine. The risk factors (smoking, 
occupational factors, infections, inflammation, radiation exposure and others) play a major role 
in tumor development and progression. This cancer type shows the highest incidence, reported 
within an occupational environment (Dye industry employees). Moreover, it is the first 
evidence –based cancer that has proven an infectious etiology of the Schistosoma haematobium 
parasite, as well as the interaction between exposure to environmental factors and genetic 
polymorphism has been demonstrated. The environmental harmful substances, toxic workplace 
conditions and lifestyle particularities might increase the risk of bladder cancer.  
Aim of the study. To assess the risk factors in patients diagnosed and treated for bladder 
cancer.  
Materials and methods.. Over the 04.2018 - 06.2019 period, 103 patients diagnosed with 
bladder cancer were admitted within the Urology Clinic of "N. Testemitanu" SUMPh. The risk 
factors, living conditions, age and other parameters were analyzed.  
Results. Out of 103 patients, 28 (27.2%) were females and 75 (72.8%) were males. The most 
vulnerable studied age-groups was over 60 years, whereas the mean age was lower in men- 
64.7 years (from 28 years to over 80 years) and 68.2 years (from 41 to over 80 years) was for 
women. According to the patient’s residence place, the study results were as following: urban- 
62 cases (60.2%) and rural 41 cases (39.8%). Out of 103 patients, 48 (46.6%) patients used 
tobacco, of which 10 -women (35.7%) and 38- men (50.7%). According to the occupational 
factors (i.e. dyes, rubber, textile, furniture and other industries), 9 (8.7%) patients out of 103 
were identified, 2-women and 7- men. No patients with infectious etiology of Schistosoma 
haematobium parasite were reported, which are more commonly encountered in endemic areas.  
Conclusions. Based on the aforementioned data, it should be mentioned that bladder cancer 
occurs more often in men with a mean age over 65, particularly from urban areas. The main 
risk factors for developing bladder cancer are as following: smoking and other harmful habits, 
occupational factors, infections, inflammation, radiation exposure, etc. The preventive 
measures consist of minimizing the risk factors. Smoking cessation is the most effective 
measure to prevent bladder cancer. The improvement of working conditions and protective 
measures might also prevent certain cases of occupational exposure. A total water intake of 2 
litres per day, as well as frequent urination (more than 4 times a day) are crucial.  
Key words: bladder tumors, risk factors  
 
